A novel intranasal Protollin™-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

被引：41

作者：

Chabot, S

Brewer, A

Lowell, G

Plante, M

Cyr, S

Burt, DS

Ward, BJ

机构：

[1] McGill Univ, Montreal Gen Hosp, Res Inst, Dept Trop Med, Montreal, PQ H3G 1A4, Canada

[2] ID Biomed Corp Quebec, St Laurent, PQ, Canada

来源：

VACCINE | 2005年 / 23卷 / 11期

基金：

加拿大健康研究院;

关键词：

vaccine; measles; adjuvants; mucosal vaccination; neutralization; antibody; IgA; interferon-gamma;

D O I：

10.1016/j.vaccine.2004.09.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Protollin-MV is a vaccine produced by mixing split measles virus (MV) antigen with the novel adjuvant Protollin(TM) (Neisseria meningitidis outer membrane proteins non-covalently complexed with Shigella flextneri 2a lipopolysaccharide). Intranasal immunization of mice with two or three doses of Protollin-MV induces both serum IgG and mucosal IgA with strong neutralizing activity. There is a dose-dependent shift towards lower IgG(1):IgG(2a), ratios and MV-specific IFNgamma production in splenocytes. Intranasal Protollin-MV can therefore induce systemic and mucosal neutralizing antibody responses as well as elicit a balanced T-H 1/T(H)2-type response. (C) 2004 Published by Elsevier Ltd.

引用

页码：1374 / 1383

页数：10

共 45 条

[1] PERSISTENCE OF MATERNAL ANTIBODY IN INFANTS BEYOND 12 MONTHS - MECHANISM OF MEASLES-VACCINE FAILURE [J].